Cancer Risk in Diabetic Patients Treated with Metformin: A Systematic Review and Meta-analysis
Open accessThe DOI matches its Crossref record; 105 of the 106 references it cites were found in a registry or an index.
Abstract
BACKGROUND: A growing body of evidence has suggested that metformin potentially reduces the risk of cancer. Our objective was to enhance the precision of estimates of the effect of metformin on the risk of any-site and site-specific cancers in patients with diabetes. METHODS/PRINCIPAL FINDINGS: We performed a search of MEDLINE, EMBASE, ISI Web of Science, Cochrane Library, and ClinicalTrials.gov for pertinent articles published as of October 12, 2011, and included them in a systematic review and meta-analysis. We calculated pooled risk ratios (RRs) for overall cancer mortality and cancer incidence. Of the 21,195 diabetic patients reported in 6 studies (4 cohort studies, 2 RCTs), 991 (4.5%) cases of death from cancer were reported. A total of 11,117 (5.3%) cases of incident cancer at any site were reported among 210,892 patients in 10 studies (2 RCTs, 6 cohort studies, 2 case-control studies). The risks of cancer among metformin users were significantly lower than those among non-metformin users: the pooled RRs (95% confidence interval) were 0.66 (0.49-0.88) for cancer mortality, 0.67 (0.53-0.85) for all-cancer incidence, 0.68 (0.53-0.88) for colorectal cancer (n = 6), 0.20 (0.07-0.59) for hepatocellular cancer (n = 4), 0.67 (0.45-0.99) for lung cancer (n = 3). CONCLUSION/SIGNIFICANCE: The use of metformin in diabetic patients was associated with significantly lower risks of cancer mortality and incidence. However, this analysis is mainly based on observational studies and our findings underscore the more need for long-term RCTs to confirm this potential benefit for individuals with diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Metformin may also confer a decreased cancer risk in patients with diabetes (90).”
From Cellular Senescence in Type 2 Diabetes: A Therapeutic Opportunity (2015) · cites this paper as [90]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164 · cited 1×
“All the procedures were in accordance with the guidelines for the Quality of Reporting of Meta-analyses [24], the meta-analysis of observational studies in epidemiology [25] and the PRISMA statement [26].”
MethodDermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Meta-analysis of Observational Studies in Epidemiology<SUBTITLE>A Proposal for Reporting</SUBTITLE>
Stroup, D. F. (2000) · JAMA · doi:10.1001/jama.283.15.2008 · Cited by 20,623
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., & Vandenbroucke, J. P. (2008) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2007.11.008 · Cited by 17,893
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · Annals of Internal Medicine · doi:10.7326/0003-4819-147-8-200710160-00010 · Cited by 17,796
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00136 · Cited by 10,349
Lopez, A. D., Mathers, C. D., Ezzati, M., Jamison, D. T., & Murray, C. J. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68770-9 · Cited by 5,630 · cited 1×
“In light of the fact that cancer is the second and diabetes the twelfth leading cause of death worldwide [59] and that the number of people with diabetes is”
Background
Cited by
Items 501–580 of 580
Suissa, S., & Azoulay, L. (2013) · Diabetes Care · doi:10.2337/dc12-2262 · Cited by 1
What do we mean by normal? The mathematical concept and social dimension of normality.
Black, P. A. (1994) · PubMed · Cited by 1
Diabetes mellitus e câncer de cabeça e pescoço
Figueiredo, R. A. D. O. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.6.2016.tde-26022016-141353 · Cited by 2
Low Expression of PDHX is Associated with Poor Prognosis and Immune Infiltration in Gastric CancerPreprint
Sun, B., Li, B., Long, Z., Zhang, C., Sun, Q., Ren, J. T., & Wang, D. (2021) · Research Square · doi:10.21203/rs.3.rs-889509/v1 · Cited by 1
Metformin Arrests Growth and Induces Apoptosis of Neuroblastoma Cells
Al-Sammarraie, N. (2014) · Scholar Commons (University of South Carolina)
Eucker, J. (2013) · Universitätsbibliothek der FU Berlin Hochschulschriftenstelle u. Dokumentenserver · doi:10.17169/refubium-12117 · Cited by 1
Crespo-Sanjuán, J. (2012) · UVaDOC UVaDOC University of Valladolid Documentary Repository (University of Valladolid) · doi:10.35376/10324/2622
Gordon-Dseagu, V. (2014) · UCL Discovery (University College London)
Lai, S., & Liao, K. (2013) · Diabetes Care · doi:10.2337/dc12-1978
Moleculair werkingsmechanisme van metformine: oude of nieuwe inzichten?
Rena, G., Pearson, E. R., & Sakamoto, K. (2013) · Nederlands Tijdschrift voor Diabetologie · doi:10.1007/s12467-013-0061-3
Jung, J. T. (2012) · Korean Journal of Gastroenterology · doi:10.4166/kjg.2012.60.6.343
“88).(5) 당뇨가 있는 대장암 환자에서 metformin 복용이 사망률을 낮출 수 있는가에 대한 연구에서 metformin을 복용한 군이 metformin을 복용하지 않은 군에 비해 전체 사망률 및 대장암과 연 관된 사망률 모두가 의미있게 감소한 것으로 보고하였다.”
Heresbach, D., & Bulois, P. (2014) · Acta Endoscopica · doi:10.1007/s10190-014-0401-1
Stümvoll, M., & Scherbaum, W. A. (2015) · Der Diabetologe · doi:10.1007/s11428-015-1344-7
Noto, H., Goto, A., Tsujimoto, T., & Noda, M. (2013) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.102.869
Self-citationDiabets and the incidence of cancer in a Portuguese urban cohort
Barros, S. R. M. (2013) · Portuguese National Funding Agency for Science, Research and Technology (RCAAP Project by FCT) · doi:10.34626/thz6-m088
Junaid, M. (2016) · University of Birmingham Institutional Research Archive (University of Birmingham) · Cited by 1
Teta, P. T. A. (2015) · Pancreatic Disorders and Therapy · doi:10.4172/2165-7092.s5-001
Systemic Therapies to Reduce the Risk of Recurrence in Early Breast Cancer: New Strategies
Chaabouni, N. K. E., Nikolaou, C., & Harries, M. (2016) · Springer eBooks · doi:10.1007/978-3-319-41858-2_7
Combination Therapeutic Strategies Targeting Growth and Metabolic Pathways in Prostate Cancer
Canatsey, R. D. (2016) · UA Campus Repository (The University of Arizona)
Mayer, M. (2016) · TSpace (University of Toronto)
Risk factors for oral HPV persistence and HPV-associated cancer
Lam, J. O. (2016)
Chun, P. (2015) · Korean Journal of Clinical Pharmacy
Metformin revisited : an ‘old’ drug with a ‘new’ beginning
Vella, S. (2013) · OAR@UM (University of Malta)
Krentz, A. J., & Sinclair, A. J. (2017) · Wiley eBooks · doi:10.1002/9781118954621.ch21
Metformin and Prostate Cancer among Diabetic Men
Margel, D. (2014) · TSpace (University of Toronto)
A metformin lehetséges haszna az onkológiai kezelésben
Balogh, Z., Sira, L., & Paragh, G. (2013) · University of Debrecen Electronic Archive (University of Debrecen)
Burn-Induced Muscle Wasting: Changes in Muscle Progenitor Cells
Yousuf, Y. (2018) · TSpace (University of Toronto)
Insight in disease and drug interactions, with treatment optimisation of patients with cancer
Knapen (2019) · Research Publications (Maastricht University) · doi:10.26481/dis.20190510lk
Type 2 diabetes mellitus and gastrointestinal cancer: Disease, drugs, or distortion?
de Jong (2019) · Research Publications (Maastricht University) · doi:10.26481/dis.20190605rj
“For instance, the incidence of esophageal adenocarcinoma has increased in recent years, whereas the incidence of esophageal squamous cell carcinoma has markedly decreased.(37) In general, a modestly increased risk of esophageal cancer in type 2 diabetic patients (summary relative risk 1.”
BackgroundResultResearch Progress on Anti-Tumor Effect of Metformin in Gastric Cancer
贺, 礼. (2019) · Advances in Clinical Medicine · doi:10.12677/acm.2019.97128
“7%。Wu 等人[9]在 2015 年的 一项荟萃分析中评估了二甲双胍在 2 型糖尿病患者中的使用情况,结果显示,与未接受二甲双胍治疗的 糖尿病患者相比,接受二甲双胍治疗的糖尿病患者的发病率降低了 14%,死亡率降低了 30%。此外,其 他荟萃分析[10] [11] [12] [13]也得到了类似的结果,表明二甲双胍总体上降低了患癌症的风险。虽然一些”
de Kort (2019) · Research Publications (Maastricht University) · doi:10.26481/dis.20190704sk
Balarezo, L. F. G. (2019) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/d.17.2019.tde-23102019-170254
Glycemic Index, Glycemic Load, and Cancer Prevention
Philippou, E. (2016) · Figshare · doi:10.1201/9781315371764-15
Tatar, B., & Gunes, S. O. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-819753-0.00016-7
Metformin – nichtglykämische Wirkungen
Joost, H. (2021) · Der Diabetologe · doi:10.1007/s11428-020-00711-x
Metformin – nichtglykämische Wirkungen
Joost, H. (2021) · Der Kardiologe · doi:10.1007/s12181-021-00497-2
Iqbal, S., Aziz, R. S., Mukhtar, R., Naqvi, F., & Rana, M. (2018) · The Professional Medical Journal · doi:10.29309/tpmj/18.4270
Glycemic Index, Glycemic Load, and Cancer Prevention
Philippou, E. (2016) · CRC Press eBooks · doi:10.1201/9781315371764-8
Effect of Immortal Time Bias Controlled Metformin for Cancer Development in Diabetic Patients
Seo, H. J. (2022) · Daehan imsang geon-gang jeungjin hakoeji/Daehan imsang geon'gang jeungjin haghoeji · doi:10.15384/kjhp.2022.22.1.40
Saito, A., Kitayama, J., Horie, H., Koinuma, K., Ohzawa, H., Yamaguchi, H., Kawahira, H., Mimura, T., Lefor, A. K., & Sata, N. (2021) · Journal of Surgery and Research · doi:10.26502/jsr.10020182 · Cited by 1
Optimizing the treatment of oesophageal cancer: New insights and the role of hypoxia
Lien, V. D. V. (2020) · Research Publications (Maastricht University) · doi:10.26481/dis.20200506lv
Pharmacological approaches for correction of thyroid dysfunctions in diabetes mellitus
Shpakov, A. O. (2017) · Biochemistry (Moscow) Supplement Series B Biomedical Chemistry · doi:10.1134/s1990750817040059 · Cited by 1
Onkodiabetológia II. Antidiabetikumok és rákmegelőzés
Bánhegyi, R. J., Gazdag, A., Rácz, B., Szalai, L., Wagner, R. J., & Fülöp, N. (2022) · Orvosi Hetilap · doi:10.1556/650.2022.32041 · Cited by 2
Mechanisms and Evidence on Pancreatic Cancer Prevention
Hasanov, M., Montiel, M. F., Bhutani, M. S., & McAllister, F. M. (2022) · Springer eBooks · doi:10.1007/978-3-031-05724-3_25
The Effect of NSAIDS and Oral Hypoglycemic Agent on Leukemia and Lymphoma Cell Lines
Khaleel, K. J., Ahmed, A. A. Q., Mohammad, M. H., & Fadhel, A. A. (2023) · International Journal of Drug Delivery Technology · doi:10.25258/ijddt.13.1.19
Qin, L., Fan, Q., & Wu, J. W. (2023) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1155/2023/5575513
Shiba, S., Kitayama, J., Harao, M., Saito, A., SAKURAGI, M., Lefor, A. K., & Sata, N. (2023) · Research Square · doi:10.21203/rs.3.rs-3271592/v1
János, B. R. (2023) · Pesci Egyetemi Archivum (University of Pécs) · doi:10.15170/pte.2023.004
Clinical potentials of metformin in cancer therapy
Sharma, N., & Dhingra, R. (2023) · Journal of Diabetology · doi:10.4103/jod.jod_84_23
Selective cytotoxicity : role of mitochondria and energy status
Assi, A. A. (2023) · theses.fr (ABES) · doi:10.70675/4398f2c9z85e1z45b4z97efz28aadb72127c
Çağlayan, M., & Eren, O. Ö. (2023) · doi:10.69860/nobel.9786053359111.43
The potential of metformin nanoformulations for cancer prevention and therapy
Hejazian, S. M., Pouya, P., Vahed, S. Z., Abdollahinia, E. D., Pakchin, P. S., Bagheri, Y., Goshtasbi, H., Dizaj, S. M., Yazdani, J., Sharifi, S., et al. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106265 · Cited by 1
Hussain, M. R., Abdelgadir, O., Kuo, Y., Canfield, S. E., & López, D. S. (2025) · Scientific Reports · doi:10.1038/s41598-025-09393-1 · Cited by 1
Khan, A. A., Sarkar, E., Chandra, A., RAZA, T., Mahdi, A. A., Agarwal, P., Sankhwar, S., & Gupta, A. K. (2025) · SSRN Electronic Journal · doi:10.2139/ssrn.5385346
The role of metformin in dysplastic mucosa of the larynx: A follow up study
Kirke, D. N., Shaari, D. S., Din‐Lovinescu, C., Blitzer, A., & Strome, M. (2025) · American Journal of Otolaryngology · doi:10.1016/j.amjoto.2025.104769
Singh, A., Gu, J. J., Zhang, Q., Torka, P., Sundaram, S., Mavis, C. K., & Hernandez‐Ilizaliturri, F. J. (2020) · Figshare · doi:10.6084/m9.figshare.12612613
Metabolic adaptation and its role in tumorigenesis
Griss, T. (2018) · eScholarship@McGill (McGill) · doi:10.82308/5521
Fait, V. (2017) · Qucosa (Saxon State and University Library Dresden)
Role of Physical Exercise and Metformin in in vitro models of tumor progression control
Baldelli, G. (2019) · CINECA IRIS Institutional Research information system (University of Urbino)
Vpliv izbranih dejavnikov na protitumorno delovanje metformina v celični kulturi rakavih celic
Kešar, U. (2020) · Repository of the University of Ljubljana (University of Ljubljana)
CHAO, R. (2024) · Institutional Repositories DataBase (IRDB) · doi:10.18926/67034
Metformin as a Senotherapeutic Agent
Turgut, Ş., Atasever, E., Andican, G., & Çakatay, U. (2026) · Healthy ageing and longevity · doi:10.1007/978-3-032-11608-6_16
Emerging role of novel candidates for diabetes mitigation
Banerjee, A., Chattopadhyay, R., Chatterjee, S., & Sen, T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44665-8.00014-6
Simonet, S. (2018) · theses.fr (ABES) · doi:10.70675/791e42afzc736z4d97zb3ccz2fb0fb5f761d · Cited by 3
“Again, surprising results were obtained, as patients taking the drug metformin, an inhibitor of complex I of the ETC, have a reduced risk of cancer incidence and mortality (Noto et al., 2012; El-Mir et al., 2000; Owen et al., 2000).”
ResultModulation of tumor immunogenicity with AMPK activation in acute myeloid leukemia
Mondésir, J. (2021) · theses.fr (ABES) · doi:10.70675/2693bda5ze768z4bf0z857bze1eb8ccccc80
EVT-701 : targeting electron transport chain complex I as therapeutic approach in cancer
Yolba, R. L. (2021) · theses.fr (ABES) · doi:10.70675/9cadea77z03ccz4a54zb381zf34a432615a5 · Cited by 2
Diabetes mellitus and neoplastic diseases
Křivanová, A. (2026) · Onkologie · doi:10.36290/xon.2026.021
Michetti, F., Strippoli, R., Zwergel, C., Rumio, C., Cordani, M., & Marcucci, F. (2026) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2026.108375 · Cited by 1
Yoshikawa, A., Okita, K., Tsuneda, K., Fujita, S., Takahara, M., Kozawa, J., Watanabe, N., Shimomura, I., & Kawata, S. (2026) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2026.113449
Recent advances in nanomaterial delivery systems to administer metformin for cancer therapy
Vozgirdaite, D., Hervé-Aubert, K., Gros, L., & Allard-Vannier, É. (2026) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2026.103009
Remodeling the Immune Landscape: How Obesity-Induced SASPs Create a Pro-Tumorigenic Niche
El-Fattah, E. E. A., Ngai, G., Mooney, R., & Aboody, K. S. (2026) · Current Obesity Reports · doi:10.1007/s13679-026-00750-3 · Cited by 1
“…prescribed insulin-sensitizing agent, has shown consistent associations with reduced cancer incidence and improved oncological outcomes in retrospective and observational studies of patients with type 2 diabetes, with particular evidence in colorectal, breast, and endometrial cancers [212, 213].”
Liu, L., Chen, H., Wang, J., Yang, J., Zhou, Y., Luo, B., Zhou, Y., & Hu, K. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1904534
“…— an umbrella review found signi fi cantly increased risk in 20 of 27 meta-analyses (35) — and metformin use is associated with lower cancer incidence and mortality (pooled relative risk for cancer mortality 0.66) (36), implicating hyperinsulinaemia and IGF-1 signalling as the shared driver (37).”
InfluentialMetformin Suppresses Metastatic Potential and Sensitizes Ovarian Cancer Cells to Chemotherapeutics
Pandya, M. J., Ogunsanya, A., Ajibade, A., & Padmanabhan, A. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27177779
“Several epidemiological studies have reported a reduced incidence of cancer among patients with diabetes who are treated with metformin [11–13].”
Cozma, D. C., Tudoran, C., & Văcărescu, C. (2026) · Current Issues in Molecular Biology · doi:10.3390/cimb48101008
“[57].”
Effect of Antidiabetic Medications on Cancer Risk: Mechanisms and Clinical Evidence
Chandra, S. (2026) · Journal of chemical health risks
Biases affecting signal detection and real-world analyses
Antonazzo, I. C., & Ferrara, P. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-26588-4.00007-3
Mitsuhashi, A., Yamagami, W., Inaba, Y., Mikami, Y., Habu, Y., Shigeta, S., Akiyama, A., Yanaihara, N., Yamaguchi, M., Tsuda, N., et al. (2026) · Gynecologic Oncology · doi:10.1016/j.ygyno.2026.10.004
Epidemiologie und molekulare Pathogenese des hepatozellulären Karzinoms
Vogel, A., & Manns, M. P. (2012) · Die Gastroenterologie · doi:10.1007/s11377-012-0647-0
Metadata
- Authors
- Noto, H., Goto, A., Tsujimoto, T., & Noda, M.
- Affiliations
- National Center for Global Health and Medicine (JP)
- Corresponding author
- Noto, Hiroshi
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-03-20
- Volume
- 7
- Issue
- 3
- Pages
- e33411
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3308971
- OpenAlex
- W2040608814
- Cited by
- 566
- References
- 106
- Citations by year
- 2026: 16 · 2025: 15 · 2024: 20 · 2023: 29 · 2022: 28 · 2021: 33 · 2020: 41 · 2019: 38 · 2018: 28 · 2017: 50 · 2016: 60 · 2015: 57 · 2014: 60 · 2013: 65 · 2012: 25
- FWCI
- 6.04
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Ministry of Health, Labour and Welfare
- Japan Diabetes Foundation
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Oncology › Cancer Risks and Factors
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Keywords
- metformin, diabetes mellitus, cancer risk, cancer mortality, cancer incidence, colorectal cancer, hepatocellular carcinoma, lung cancer, chemoprevention
- MeSH terms
- Clinical Trials as Topic, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Metformin, Neoplasms, Risk Factors, Meta-Analysis as Topic, Incidence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.